Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker COGT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 22, 2026 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506 · PIK3CA Mutations, Advanced Solid Tumors, Adult CGT6297 | COGT Cogent Biosciences, Inc. | Phase 1 | Recruiting | 90 | Jul 2029 | Registry ↗ |
| Oct 22, 2026 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Ind… NCT05186753 · SSM, Mastocytosis, Indolent Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablet… | COGT Cogent Biosciences, Inc. | Phase 2 | Active, not recruiting | 237 | May 22, 2025 | Registry ↗ |
| Sep 15, 2026 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis NCT04996875 · Advanced Systemic Mastocytosis (AdvSM), SM With an Associat… bezuclastinib | COGT Cogent Biosciences, Inc. | Phase 2 | Recruiting | 140 | Sep 19, 2025 | Registry ↗ |
| Sep 4, 2026 | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562 · Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer CGT4255 | COGT Cogent Biosciences, Inc. | Phase 1 | Recruiting | 100 | May 2028 | Registry ↗ |
| Jul 13, 2026 | Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointest… NCT06948955 · Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors Bezuclastinib, Sunitinib | COGT Cogent Biosciences, Inc. | — | Available | — | — | Registry ↗ |
| Jul 13, 2026 | Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Sy… NCT06915766 · Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Agg… Bezuclastinib | COGT Cogent Biosciences, Inc. | — | Available | — | — | Registry ↗ |
| Jun 16, 2026 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointesti… NCT05208047 · Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer CGT9486, CGT9486 | COGT Cogent Biosciences, Inc. | Phase 3 | Recruiting | 482 | Sep 30, 2025 | Registry ↗ |
| Apr 17, 2026 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced So… NCT06777316 · Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma CGT4859 | COGT Cogent Biosciences, Inc. | Phase 1/2 | Active, not recruiting | 110 | Mar 2027 | Registry ↗ |
| Feb 14, 2025 | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib… NCT02401815 · Gastrointestinal Stromal Tumors CGT9486, Pexidartinib | COGT Cogent Biosciences, Inc. | Phase 1/2 | Completed | 51 | May 11, 2020 | Registry ↗ |
| Oct 11, 2021 | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymph… NCT03189836 · Lymphoma ACTR707, rituximab | COGT Cogent Biosciences, Inc. | Phase 1 | Terminated | 26 | Sep 21, 2020 | Registry ↗ |
| Oct 11, 2021 | Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product NCT02840110 · B Cell Lymphomas, Multiple Myeloma ACTR T Cell Product | COGT Cogent Biosciences, Inc. | — | Terminated | 22 | Oct 23, 2020 | Registry ↗ |
| Mar 31, 2020 | Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advance… NCT03680560 · Solid Tumor, HER-2 Protein Overexpression ACTR T Cell Product, Trastuzumab | COGT Cogent Biosciences, Inc. | Phase 1 | Terminated | 6 | Mar 12, 2020 | Registry ↗ |
| Mar 31, 2020 | Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma NCT02776813 · Lymphoma ACTR087, rituximab | COGT Cogent Biosciences, Inc. | Phase 1 | Completed | 34 | Feb 12, 2020 | Registry ↗ |
| Mar 30, 2020 | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myel… NCT03266692 · Multiple Myeloma, Multiple Myeloma in Relapse ACTR087, SEA-BCMA | COGT Cogent Biosciences, Inc. | Phase 1 | Terminated | 15 | Oct 1, 2019 | Registry ↗ |
14 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:21 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances